Verition Fund Management LLC Has $269,000 Stock Position in Pediatrix Medical Group, Inc. (NYSE:MD)

Verition Fund Management LLC lessened its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 75.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,220 shares of the company's stock after selling 73,004 shares during the quarter. Verition Fund Management LLC's holdings in Pediatrix Medical Group were worth $269,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in MD. Quest Partners LLC lifted its holdings in shares of Pediatrix Medical Group by 25.6% in the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company's stock valued at $35,000 after buying an additional 622 shares during the period. nVerses Capital LLC acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at approximately $31,000. Innealta Capital LLC acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at approximately $33,000. Nisa Investment Advisors LLC raised its holdings in Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock worth $36,000 after purchasing an additional 1,524 shares during the last quarter. Finally, CWM LLC raised its holdings in Pediatrix Medical Group by 134.0% during the third quarter. CWM LLC now owns 6,427 shares of the company's stock worth $74,000 after purchasing an additional 3,681 shares during the last quarter. Hedge funds and other institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Stock Down 0.7 %

Shares of MD traded down $0.10 during mid-day trading on Friday, reaching $14.07. The company's stock had a trading volume of 323,416 shares, compared to its average volume of 851,323. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $16.41. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -4.60, a price-to-earnings-growth ratio of 2.02 and a beta of 1.57. The business has a fifty day moving average of $13.96 and a 200 day moving average of $10.75.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business's quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business posted $0.29 earnings per share. As a group, analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft lifted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a "hold" rating in a report on Monday, November 4th. StockNews.com raised Pediatrix Medical Group from a "hold" rating to a "buy" rating in a research report on Wednesday. UBS Group boosted their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Jefferies Financial Group boosted their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Finally, Truist Financial boosted their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a "hold" rating in a research note on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, Pediatrix Medical Group has an average rating of "Hold" and a consensus price target of $16.10.

Insider Activity

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the firm's stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now owns 138,683 shares of the company's stock, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by company insiders.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.